A Single Institution's Long-term Follow-up of Patients with Pathological Complete Response in Locally Advanced Rectal Adenocarcinoma Following Neoadjuvant Chemoradiotherapy
Overview
General Surgery
Authors
Affiliations
Purpose: This paper aimed to study the long term follow-up of patients with primary rectal adenocarcinoma receiving neoadjuvant chemoradiotherapy who obtained a pathological complete response (pCR) and identify factors predicting complete response.
Methods: Retrospective review of notes, histology, pre-operative full blood count and imaging of patients with primary rectal adenocarcinoma diagnosed in our institute from 2000 to 2012 from a prospectively maintained database were used. SPSS version 22.0 was used for statistical analysis.
Results: Three hundred eighty patients diagnosed with primary rectal adenocarcinoma were identified, 277 received neoadjuvant chemoradiotherapy followed by curative resection. Forty-six patients obtained a pCR (ypT0N0) with no local recurrence and two metastatic recurrences on follow-up. Patients with a pCR have a significantly improved overall survival and disease-free survival compared to a non-pCR (150.0 and 136.1 vs 77.5 and 84.7 months, p = 0.001). On univariate analysis, increased tumour height above anal verge, low lymph node yield, high pre-operative haemoglobin and a low neutrophil-lymphocyte ratio are significant factors identifying a pCR. Multivariable analysis of the above factors confirmed tumour height above anal verge as significant in obtaining a pCR.
Conclusion: Patients with rectal adenocarcinoma who develop a pCR following neoadjuvant chemoradiotherapy have improved overall and disease-free survival. We have identified distance from anal verge, low lymph node yield, high pre-operative haemoglobin and low neutrophil-lymphocyte ratio as significant predictors of developing a pCR.
Pian G, Oh S Oncol Lett. 2024; 28(4):447.
PMID: 39101000 PMC: 11292465. DOI: 10.3892/ol.2024.14580.
Wang K, Li M, Yan J J Gastrointest Cancer. 2022; 54(3):791-801.
PMID: 36103002 PMC: 10613134. DOI: 10.1007/s12029-022-00861-9.
Emons G, Auslander N, Jo P, Kitz J, Azizian A, Hu Y Br J Cancer. 2022; 127(4):766-775.
PMID: 35597871 PMC: 9381580. DOI: 10.1038/s41416-022-01842-2.
Lee S, Kim K, Park H Front Oncol. 2022; 12:778607.
PMID: 35223468 PMC: 8873579. DOI: 10.3389/fonc.2022.778607.
Management of early rectal cancer; current surgical options and future direction.
Chavda V, Siaw O, Chaudhri S, Runau F World J Gastrointest Surg. 2021; 13(7):655-667.
PMID: 34354799 PMC: 8316852. DOI: 10.4240/wjgs.v13.i7.655.